Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omarigliptin add-on to insulin in Japanese T2DM
NCT02906709Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Omarigliptin 25 mg with Placebo -> Omarigliptin 25 mg (2 arms). Primary endpoints: Change From Baseline in Hemoglobin A1c at Week 16, Percentage of Participants Who Experienced One or More Adverse Events (Phase A) at 16 weeks and 3 more. Started Oct 2016; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02906709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906709.